Cartesian Therapeutics (RNAC) Research & Development (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Research & Development data on file, last reported at $19.5 million in Q1 2026.

• On a quarterly basis, Research & Development rose 32.64% year-over-year to $19.5 million in Q1 2026; TTM through Mar 2026 was $62.8 million, a 25.54% increase from a year earlier, with the FY2025 full-year figure at $58.0 million, up 28.66% from the prior year.
• Research & Development for Q1 2026 stood at $19.5 million, up from $14.7 million in the prior quarter.
• Over the last five years, Research & Development for RNAC reached as high as $21.9 million in Q4 2023 and fell as low as $9.7 million in Q1 2024.
• Historically, Research & Development has averaged $15.7 million across 5 years, with a median of $14.9 million in 2025.
• Across the five-year window, Research & Development plunged 48.26% in 2024 and soared 50.69% in 2025, its largest moves.
• Year by year, Research & Development stood at $19.0 million in 2022, then advanced by 15.21% to $21.9 million in 2023, then plunged by 48.26% to $11.3 million in 2024, then gained by 29.92% to $14.7 million in 2025, then jumped by 32.5% to $19.5 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $19.5 million in Q1 2026, $14.7 million in Q4 2025, and $13.8 million in Q3 2025.